The US expects to be able to provide at no cost more than 1 million doses of antibody treatments for COVID-19 similar to the one President Donald Trump received to treat his bout with the illness, as reported in London South East.
Department of Health and Human Services official Paul Mango said the government's Operation Warp Speed program currently has "a couple of hundred thousand doses" of the monoclonal antibody treatments being developed by Regeneron Pharmaceutical and Eli Lilly.
Both companies have said the drugs were shown to work in clinical trials and that they have submitted an emergency-use authorization requests to the FDA.
If the drugs are authorized for use by the FDA, Mango said that the government will allocate the treatments to the states based on need, similar to the mechanism used with Gilead Sciences' antiviral drug remdesivir for COVID-19.
Regeneron signed a $450-million deal in July to sell Operation Warp Speed enough doses of its antibody treatment, REGN-COV2, to treat around 300,000 people.
Eli Lilly said on Friday it has not signed an agreement with Operation Warp Speed regarding its LY-CoV555 treatment. It said recently that it expects to produce around 1 million doses of the therapy this year.
To read more NewsPoints articles, click here.